Results 61 to 70 of about 44,760 (265)
HMGB1 is a potent trigger of arthritis [PDF]
Abstract.Rheumatoid arthritis is a chronic inflammatory disease characterized by synovial inflammation and structural damage of joints. Although the cause of rheumatoid arthritis (RA) remains unknown, the excessive production of proinflammatory cytokines such as tumour necrosis factor (TNF) and interleukin‐1 (IL‐1) by intra‐articular macrophages ...
U, Andersson, H, Erlandsson-Harris
openaire +2 more sources
This work proposes a novel strategy to fabricate unimolecular pyroptosis photoinitiators activated by deep‐red light at low light doses. It relies on a photosensitization mechanism to trigger nitric oxide (NO) release from benzisothiadiazole‐based N‐nitrosanilines without modification of nitro moieties, thereby boosting pyroptosis‐mediated ...
Chuangxin Zhang +4 more
wiley +1 more source
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee +6 more
wiley +1 more source
Regulation of HMGB1 release by inflammasomes [PDF]
High mobility group box 1 (HMGB1) is an evolutionarily conserved non-histone chromatin-binding protein. During infection or injury, activated immune cells and damaged cells release HMGB1 into the extracellular space, where HMGB1 functions as a proinflammatory mediator and contributes importantly to the pathogenesis of inflammatory diseases.
Ben, Lu +3 more
openaire +2 more sources
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
Weixin Hou,1– 4 Xiaoyi Wei,1,2 Jiajun Liang,1– 4 Peng Fang,5 Chongyang Ma,1,2 Qiuyun Zhang,1,2,* Yanbin Gao3,4,* 1Department of Hepatology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, People’s Republic of China ...
Hou W +6 more
doaj
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu +13 more
wiley +1 more source
Role of HMGB1 in Vitiligo: Current Perceptions and Future Perspectives
Guangmin Wei,1 Yinghao Pan,2 Jingying Wang,2 Xia Xiong,2 Yuanmin He,2 Jixiang Xu2 1Department of Dermatology, Medical Center Hospital of Qionglai City, Qionglai, Sichuan, People’s Republic of China; 2Department of Dermatology, The Affiliated Hospital of ...
Wei G +5 more
doaj
Schematic illustration of the Pluronic F127 diacrylate/gelatin methacryloyl/poly(3,4‐ethylenedioxythiophene):poly(styrenesulfonate)/celastrol hydrogel (FGPC) for localized myocardial ischemia–reperfusion injury treatment. FGPC combines sustained celastrol delivery with PEDOT:PSS‐mediated conductive support to attenuate acute oxidative/inflammatory ...
Shixin Wang +10 more
wiley +1 more source
High mobility group box 1 (HMGB1), a highly conserved nuclear protein, is released into the extracellular milieu serving as a modulator of inflammatory responses. HMGB1 levels are elevated in the airspaces of CF patients and mice with cystic fibrosis (CF)
Yun Mao, Sonika Patial, Yogesh Saini
doaj +1 more source

